Clinical Trial Update: An Open-Label Study Evaluating Breakthrough Bleeding and Spotting With Norgestimate/Ethinyl Estradiol Tablets Administered as an Extended Regimen [Phase 2]

View source ↗

Summary

Open-label Phase 2 study evaluating breakthrough bleeding and spotting with an extended-regimen norgestimate/ethinyl estradiol combination.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Abnormal Uterine Bleeding

Drugs mentioned

• Norgestimate/ethinyl estradiol (extended regimen) (norgestimate; ethinyl estradiol)

Snippet

Sponsor: McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | Conditions: Metrorrhagia | Phase 2 | Status: COMPLETED